CIC and The Yuan have jointly released their report on the Development Trend of Integrated Nuclear Medicine Diagnosis and Treatment to chart the future course of integrated nuclear medicine diagnosis and treatment, a new field that augurs great breakthroughs in fighting disease.

Radioactive substances are normally harmful, but nuclear medicine aims to take that destructive power and use it to treat - or at least diagnose - diseases. Efforts to combine this with AI to treat diseases like cancer in new and more effective ways continue to advance, and so the globally leading online AI community The Yuan has partnered with the world-renowned think tank Deep Pharma Intelligence and the world leading nuclear medicine company Evomics to put together this report, which takes an in-depth look at the latest AI applications in nuclear medicine and radiology and what the future of AI in these fields might look like, as well as the specific steps being taken by the private sector and governments around the world to help drive this development.

A pioneering new report offers an overview of pharma RWS/RCT industry developments in 2020-2021, Asia’s RWS market size, trends there and in China - where it predicts 40 percent yearly growth - and showcases Asian RWS industry leaders. It discusses use of virtual Twin Studies, GWAS, Pharmacovigilance and AI, and explores RWS and AI used in diagnostics, biomarkers, image analysis, disease prevention, and Big Data. It then cites the challenges and opportunities faced by AI-driven WRS and lists governmental regulations on RWS and Big Data in Asia.